These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 28277033)

  • 1. Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study.
    Espinoza-Zamora JR; Labardini-Méndez J; Sosa-Espinoza A; López-González C; Vieyra-García M; Candelaria M; Lozano-Zavaleta V; Toledano-Cuevas DV; Zapata-Canto N; Cervera E; Dueñas-González A
    Expert Opin Investig Drugs; 2017 Apr; 26(4):481-487. PubMed ID: 28277033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS).
    Candelaria M; Burgos S; Ponce M; Espinoza R; Dueñas-Gonzalez A
    Ann Hematol; 2017 Nov; 96(11):1825-1832. PubMed ID: 28831600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
    Olsen EA; Kim YH; Kuzel TM; Pacheco TR; Foss FM; Parker S; Frankel SR; Chen C; Ricker JL; Arduino JM; Duvic M
    J Clin Oncol; 2007 Jul; 25(21):3109-15. PubMed ID: 17577020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
    Duvic M; Talpur R; Ni X; Zhang C; Hazarika P; Kelly C; Chiao JH; Reilly JF; Ricker JL; Richon VM; Frankel SR
    Blood; 2007 Jan; 109(1):31-9. PubMed ID: 16960145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
    Damaj G; Gressin R; Bouabdallah K; Cartron G; Choufi B; Gyan E; Banos A; Jaccard A; Park S; Tournilhac O; Schiano-de Collela JM; Voillat L; Joly B; Le Gouill S; Saad A; Cony-Makhoul P; Vilque JP; Sanhes L; Schmidt-Tanguy A; Bubenheim M; Houot R; Diouf M; Marolleau JP; Béné MC; Martin A; Lamy T
    J Clin Oncol; 2013 Jan; 31(1):104-10. PubMed ID: 23109692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.
    Dueñas-Gonzalez A; Coronel J; Cetina L; González-Fierro A; Chavez-Blanco A; Taja-Chayeb L
    Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1433-44. PubMed ID: 25154405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.
    Arce C; Pérez-Plasencia C; González-Fierro A; de la Cruz-Hernández E; Revilla-Vázquez A; Chávez-Blanco A; Trejo-Becerril C; Pérez-Cárdenas E; Taja-Chayeb L; Bargallo E; Villarreal P; Ramírez T; Vela T; Candelaria M; Camargo MF; Robles E; Dueñas-González A
    PLoS One; 2006 Dec; 1(1):e98. PubMed ID: 17183730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
    Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
    Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
    Kannangara AP; Levitan D; Fleischer AB
    J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma.
    Straus DJ; Duvic M; Horwitz SM; Hymes K; Goy A; Hernandez-Ilizaliturri FJ; Feldman T; Wegner B; Myskowski PL
    Ann Oncol; 2014 Jan; 25(1):206-10. PubMed ID: 24285015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma.
    Duvic M; Kim YH; Zinzani PL; Horwitz SM
    Clin Cancer Res; 2017 Jul; 23(14):3552-3556. PubMed ID: 28167509
    [No Abstract]   [Full Text] [Related]  

  • 12. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma.
    Mann BS; Johnson JR; He K; Sridhara R; Abraham S; Booth BP; Verbois L; Morse DE; Jee JM; Pope S; Harapanhalli RS; Dagher R; Farrell A; Justice R; Pazdur R
    Clin Cancer Res; 2007 Apr; 13(8):2318-22. PubMed ID: 17438089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.
    Candelaria M; Gallardo-Rincón D; Arce C; Cetina L; Aguilar-Ponce JL; Arrieta O; González-Fierro A; Chávez-Blanco A; de la Cruz-Hernández E; Camargo MF; Trejo-Becerril C; Pérez-Cárdenas E; Pérez-Plasencia C; Taja-Chayeb L; Wegman-Ostrosky T; Revilla-Vazquez A; Dueñas-González A
    Ann Oncol; 2007 Sep; 18(9):1529-38. PubMed ID: 17761710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.
    Prince HM; Duvic M; Martin A; Sterry W; Assaf C; Sun Y; Straus D; Acosta M; Negro-Vilar A
    J Clin Oncol; 2010 Apr; 28(11):1870-7. PubMed ID: 20212249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial.
    Candelaria M; Herrera A; Labardini J; González-Fierro A; Trejo-Becerril C; Taja-Chayeb L; Pérez-Cárdenas E; de la Cruz-Hernández E; Arias-Bofill D; Vidal S; Cervera E; Dueñas-Gonzalez A
    Ann Hematol; 2011 Apr; 90(4):379-87. PubMed ID: 20922525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
    Akpek G; Koh HK; Bogen S; O'Hara C; Foss FM
    Cancer; 1999 Oct; 86(7):1368-76. PubMed ID: 10506727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results.
    Coronel J; Cetina L; Pacheco I; Trejo-Becerril C; González-Fierro A; de la Cruz-Hernandez E; Perez-Cardenas E; Taja-Chayeb L; Arias-Bofill D; Candelaria M; Vidal S; Dueñas-González A
    Med Oncol; 2011 Dec; 28 Suppl 1():S540-6. PubMed ID: 20931299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
    Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R
    J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome.
    Child F; Ortiz-Romero PL; Alvarez R; Bagot M; Stadler R; Weichenthal M; Alves R; Quaglino P; Beylot-Barry M; Cowan R; Geskin LJ; Pérez-Ferriols A; Hellemans P; Elsayed Y; Phelps C; Forslund A; Kamida M; Zinzani PL
    Br J Dermatol; 2016 Jul; 175(1):80-8. PubMed ID: 26836950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
    Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
    Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.